Results 21 to 30 of about 1,577,570 (335)

Research objectives and general considerations for pragmatic clinical trials of pain treatments: IMMPACT statement

Pain, 2023
Many questions regarding the clinical management of people experiencing pain and related health policy decision-making may best be answered by pragmatic controlled trials. To generate clinically relevant and widely applicable findings, such trials aim to
David Hohenschurz-Schmidt, D. Cherkin, A. Rice, R. Dworkin, D. Turk, M. Mcdermott, M. Bair, L. DeBar, R. Edwards, J. Farrar, R. Kerns, J. Markman, M. Rowbotham, K. Sherman, A. Wasan, P. Cowan, P. Desjardins, McKenzie C. Ferguson, R. Freeman, J. Gewandter, I. Gilron, H. Grol-Prokopczyk, S. Hertz, S. Iyengar, Cornelia L. Kamp, B. Karp, Bethea A. Kleykamp, J. Loeser, S. Mackey, R. Malamut, E. McNicol, K. Patel, F. Sandbrink, Kenneth Schmader, Lee Simon, D. Steiner, Christin Veasley, J. Vollert   +37 more
semanticscholar   +1 more source

Toward Meeting the Obligation of Respect for Persons in Pragmatic Clinical Trials.

The Hastings center report, 2022
Research ethics oversight systems have traditionally emphasized the informed consent process as the primary means by which to demonstrate respect for prospective subjects.
Stephanie R. Morain, S. Kraft, B. Wilfond, Amy Mcguire, N. Dickert, Andrew Garland, J. Sugarman   +6 more
semanticscholar   +1 more source

Design and rationale of a multi-center, pragmatic, open-label randomized trial of antimicrobial therapy - the study of clinical efficacy of antimicrobial therapy strategy using pragmatic design in Idiopathic Pulmonary Fibrosis (CleanUP-IPF) clinical trial [PDF]

, 2020
Compelling data have linked disease progression in patients with idiopathic pulmonary fibrosis (IPF) with lung dysbiosis and the resulting dysregulated local and systemic immune response.
A Mishra, AW Brown, B Ley, BA Karimi-Shah, BT Baxter, CJ Ryerson, DG Pankratz, DJ Lederer, G Raghu, G Raghu, H Scheper, HR Collard, J Andrade, J Coast, J Coast, K Loudon, K Loudon, KA Getz, KD Brandt, KE Thorpe, KF Schulz, L Richeldi, L Shulgina, LB Krupp, M Fralick, M Hammond, MA Fischl, MA Perazella, MO Paterniti, MT Durheim, P Bhattacharyya, PL Molyneaux, PL Molyneaux, PL Molyneaux, R Dal-Ré, RM Califf, RM du Bois, SD Nathan, SS Birring, T Katsuyama, TE King Jr, VA Varney, WS Jones, Y Huang   +43 more
core   +1 more source

Gatekeepers for pragmatic clinical trials [PDF]

Clinical Trials, 2015
To successfully implement a pragmatic clinical trial, investigators need access to numerous resources, including financial support, institutional infrastructure (e.g. clinics, facilities, staff), eligible patients, and patient data. Gatekeepers are people or entities who have the ability to allow or deny access to the resources required to support the
Danielle M, Whicher, Jennifer E, Miller, Kelly M, Dunham, Steven, Joffe   +3 more
openaire   +2 more sources

A first step towards best practice recommendations for the design and statistical analyses of pragmatic clinical trials: A modified Delphi approach

British Journal of Clinical Pharmacology, 2022
Pragmatic clinical trials (PCTs) are randomized trials implemented through routine clinical practice, where design parameters of traditional randomized controlled trials are modified to increase generalizability.
Victoria Palin, T. V. van Staa, S. Steels, A. Troxel, R. Groenwold, Tom M. MacDonald, D. Torgerson, D. Faries, Pierre Mancini, M. Ouwens, L. Frith, Kate Tsirtsonis, G. Maclennan, C. Nordon   +13 more
semanticscholar   +1 more source

Incentives and payments in pragmatic clinical trials: Scientific, ethical, and policy considerations

Clinical Trials, 2021
Pragmatic clinical trials are increasingly used to generate knowledge about real-world clinical interventions. However, they involve some distinctive ethical and regulatory challenges. In this article, we examine a set of issues related to incentives and
A. Garland, K. Weinfurt, J. Sugarman
semanticscholar   +1 more source

Increasing patient participation in oncology clinical trials

Cancer Medicine, 2023
Aim Timely recruitment of eligible participants is essential for the success of clinical trials, with insufficient accrual being the leading cause for premature termination of both oncology and non‐oncology trials.
Jie Chen, Ying Lu, Shivaani Kummar
doaj   +1 more source

Raising the standard of applied dementia care research : addressing the implementation error [PDF]

, 2014
Editoria
Moniz-Cook, Esme, Vernooij-Dassen, Myrra
core   +9 more sources

Justice and equity in pragmatic clinical trials: Considerations for pain research within integrated health systems

Learning Health Systems, 2021
Pragmatic clinical trials (PCTs) can overcome implementation challenges for bringing evidence‐based therapies to people living with pain and co‐occurring conditions, providing actionable information for patients, providers, health systems, and policy ...
Joseph Ali, Alison F Davis, Diana J. Burgess, Daniel I. Rhon, R. Vining, S. Young-McCaughan, S. Green, R. Kerns   +7 more
semanticscholar   +1 more source

Physicians’ perspectives regarding pragmatic clinical trials [PDF]

Journal of Comparative Effectiveness Research, 2016
Aim: Practicing physicians inevitably become involved in pragmatic clinical trials (PCTs), including comparative effectiveness research. We sought to identify physicians’ perspectives related to PCTs. Methods: In-depth semistructured interviews with 20 physicians in the USA. Results:
Rachel, Topazian, Juli, Bollinger, Kevin P, Weinfurt, Rachel, Dvoskin, Debra, Mathews, Kathleen, Brelsford, Matthew, DeCamp, Jeremy, Sugarman   +7 more
openaire   +2 more sources